System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Randomized Controlled Trial Epublish

PubMed: 39941091 DOI: 10.3390/ijms26031323

Therapeutic Potential of Bifidobacterium longum subsp. infantis B8762 on Gut and Respiratory Health in Infant.

Int J Mol Sci 26(3)

Authors: Rocky Vester Richmond, Uma Mageswary, Adli Ali, Fahisham Taib, Thai Hau Koo, Azianey Yusof, Intan Juliana Abd Hamid, Feiyan Zhao, Nik Norashikin Nik Abd Rahman, Taufiq Hidayat Hasan, Heping Zhang, Min-Tze Liong

Affiliations

  • Department of Pediactric, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.
  • School of Industrial Technology, Universiti Sains Malaysia, Gelugor 11800, Malaysia.
  • Pediatric & Palliative Care, Hospital Universiti Sains Malaysia, Kota Bharu 16150, Malaysia.
  • Kepala Batas Health Clinic, Ministry of Health Malaysia, Putrajaya 13200, Malaysia.
  • Advanced Medical & Dental Institute, Universiti Sains Malaysia, Gelugor 13200, Malaysia.
  • Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Inner Mongolia Agricultural University, Hohhot 010018, China.
  • Wakaf Che Yeh Health Clinic, Ministry of Health Malaysia, Kota Bharu 15100, Malaysia.
  • IIUM Medical Centre, International Islamic University Malaysia, Kuantan 25200, Malaysia.

Abstract

Respiratory tract and gastrointestinal infections in pediatric populations are major public health concerns. Addressing these challenges necessitates effective preventative and therapeutic strategies. This study assessed the efficacy of the probiotic Bifidobacterium longum subsp. infantis B8762 (0.5 × 10 10 CFU) in reducing the duration and frequency of these infections in young children. In a randomized trial, 115 eligible children were assigned to either the probiotic (n = 57; 3.51 ± 0.48 months old) or placebo (n = 58; 2.78 ± 0.51 months old) group, with daily consumption for 4 weeks. The probiotic group demonstrated a lower duration of infections than the placebo group (p < 0.05). The probiotic group also showed fewer clinical visits due to respiratory and gastrointestinal problems as compared to the placebo group (p = 0.009 & p = 0.004, respectively). Oral swab samples revealed that the placebo group had higher levels of pro-inflammatory cytokine TNF-α after 4 weeks (p = 0.033), while the probiotic group demonstrated a balanced cytokine response, indicating modulation of the immune system. Genomic analysis showed that B8762 harbors various genes for the synthesis of proteins and vitamins crucial for the gut health of children. Both the clinical and genomic findings suggested that B8762 offered a therapeutic effect on gut and respiratory health in children, highlighting its potential in managing common pediatric infections.

MeSH

Cytokines, Immunomodulation, Probiotics, Therapeutics, Pediatrics, Infections, Child, Infant